Novo Nordisk A/S Class B
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Maziar Mike Doustdar
- Full Time Employees
- 68,794
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Novo Alle 1 Bagsværd CR Denmark 2880
- IPO Date
- May 17, 1974
- Website
- novonordisk.com
- Similar Companies
- Business
- Novo Nordisk A/S is a global healthcare company headquartered in Bagsværd, Denmark, founded in 1923, specializing in the research, development, manufacture, and marketing of pharmaceutical products primarily focused on diabetes care, obesity, rare diseases, and biopharmaceuticals. Its main product portfolio includes diabetes and obesity care products such as insulin and GLP-1 receptor agonists (including the Ozempic and Wegovy brands); insulin delivery systems; and treatments for hemophilia, growth hormone therapy, and hormone replacement therapy. The company operates across more than 180 countries, with key markets in North America, Europe, and Asia. Recent major developments include the acquisition of cardiovascular disease-focused Cardior Pharmaceuticals and the Montreal-based biotech Inversago Pharma to expand its metabolic disorder pipeline, along with a $2.2 billion collaboration with US biotech Septerna to develop oral small molecule therapies for obesity, type 2 diabetes, and cardio-metabolic disorders. Novo Nordisk is advancing next-generation obesity drugs such as CagriSema, currently in phase 3 trials, which has demonstrated significant weight loss in clinical studies, as well as oral and injectable amycretin candidates targeting dual hormone pathways for enhanced weight management. The company has also received US and EU approvals for Alhemo® (Concizumab), for hemophilia treatment, and continues to invest substantially in R&D and production capacity to meet growing global demand, aiming to reinforce its leadership in diabetes, obesity, and emerging cardio-metabolic therapies while expanding into chronic kidney disease and metabolic dysfunction-associated steatohepatitis (MASH). Novo Nordisk’s strategic focus includes sustaining market share in GLP-1 segments, launching innovative treatments, and pursuing acquisitions and partnerships to strengthen its therapeutic areas and product offerings globally.
Company News
Novo Nordisk Just Delivered Great News for Investors. Is a Comeback Finally Underway?
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (November 2026)
Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026
Novo Nordisk Owns The Oral Weight Loss Market At 7.8x Operating Income
NVO Q3 Earnings Call Highlights GLP-1 Growth and Raised Outlook
Stock Traders Purchase High Volume of Novo Nordisk A/S Call Options (NYSE:NVO)
Novo Nordisk: 3 Key Takeaways for Long-Term Investors
Novo Nordisk Stock Jumped After Earnings — But Its CEO Won't Give 2027 Guidance. Here's What Investors Should Know
Novo Nordisk A/S (NOVO:CA) Q3 2026 Earnings Call Transcript
Novo Nordisk Stock Jumps 6% as Wegovy Hits a Stunning 80% Milestone
NVO Q3 Earnings Beat Estimates on Wegovy Pill Growth, Outlook Raised
Novo Nordisk Q3: Just The Report I Was Waiting For
GLP-1 drugs help control prediabetes better than current standard medicine
2 Reasons for Hope From Novo Nordisk Earnings
Beleaguered Novo offers relief to investors, thanks to Wegovy pill
Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues
Novo Nordisk's CFO Karsten Munk Knudsen to leave company
Novo raises full-year outlook as Wegovy sales impress
Novo Nordisk Q3 profit beats forecast; raises 2026 guidance
3 Dirt Cheap Dividend Stocks to Buy in November 2026